Pd-l1-binding molecules comprising shiga toxin a subunit scaffolds
AssigneeMolecular Templates, Inc.
InventorsEric Poma, Hilario Ramos, Erin Willert, Richard Shimkets, Crystal Jackson, Thomas Vincent
Life of this patent
Estimating the term…
Loading patent…
AssigneeMolecular Templates, Inc.
InventorsEric Poma, Hilario Ramos, Erin Willert, Richard Shimkets, Crystal Jackson, Thomas Vincent
Estimating the term…
Provided herein are PD-L1 binding molecules comprising or conjugated to a toxin, e.g. a Shiga toxin A Subunit derived polypeptide. In some embodiments, the PD-L1 binding molecules are cytotoxic. In some embodiments, the PD-L1 binding molecules are capable of delivering a CD8+ T-cell epitope to an MHC class molecule inside a PD-L1 positive cell. The PD-L1 binding molecules described herein have uses for selectively killing specific cells (e.g., PD-L1 positive tumor cells and/or immune cells); for selectively delivering cargos to specific cells (e.g., PD-L1 positive tumor cells or immune cells), and as therapeutic and/or diagnostic molecules for treating and diagnosing a variety of conditions, including cancers and tumors involving PD-L1 expressing cells (e.g., PD-L1 positive tumor cells or immune cells).
-64. (canceled)
A method of treating a disease, disorder, or condition in a subject, the method comprising a step of administering to a subject in need thereof a therapeutically effective amount of a PD-L1 binding molecule comprising a Shiga toxin effector polypeptide and a binding region capable of specifically binding an extracellular part of PD-L1;
Dependencies are inferred from the claim text.